Cormorant Asset Management’s Regenxbio RGNX Stock Holding History

Cormorant Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-120,000	Closed	-$2.37M	–	61
2017 Q2	$2.37M	Hold	120,000	–	–	0.39%	52
2017 Q1	$2.32M	Sell	120,000 -36,741	-23%	-$709K	0.34%	56
2016 Q4	$2.91M	Hold	156,741	–	–	0.39%	51
2016 Q3	$2.2M	Hold	156,741	–	–	0.24%	64
2016 Q2	$1.25M	Hold	156,741	–	–	0.18%	65
2016 Q1	$1.69M	Hold	156,741	–	–	0.26%	63
2015 Q4	$2.6M	Hold	156,741	–	–	0.31%	58
2015 Q3	$3.45M	Buy	+156,741	New	+$4M	0.55%	46

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cormorant Asset Management's RGNX Position: Q3 2017 in Review

Cormorant Asset Management sold out of Regenxbio (RGNX) in Q3 2017, closing a stake of 120,000 shares — an estimated $2.37M sold.

Cormorant Asset Management first reported a position in RGNX in Q3 2015 and held it in 8 quarters. The position peaked at $3.45M in Q3 2015. 89 funds tracked by Wall St. Rank hold RGNX as of Q3 2017.

Cormorant Asset Management reported no remaining Regenxbio position as of Q3 2017 after selling out during the quarter.
Cormorant Asset Management sold 120,000 Regenxbio shares in Q3 2017, an estimated $2.37M.
Cormorant Asset Management first reported a position in Regenxbio in Q3 2015 and held it in 8 quarters.
Cormorant Asset Management's Regenxbio position peaked at $3.45M in Q3 2015.
89 funds tracked by Wall St. Rank held Regenxbio as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.